Annual Secretarial Compliance report for the period ended on 31st Match 2025.
VENUSREM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Venus Remedies has submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2025, as required under SEBI LODR Regulation 24A. The Practicing Company Secretary (P. Chadha & Associates) reviewed the company's filings with BSE and NSE, its website, and other relevant records. The company is largely compliant across all checked areas — secretarial standards, board policies, website disclosures, related party transactions, insider trading norms, and director eligibility. One prior-year issue carried forward: during FY24, one page of the standalone P&L statement was missed in the XBRL submission to NSE under Regulation 33. NSE levied a Rs. 65,000 fine and the waiver application is still pending, while BSE levied Rs. 50,000, rejected the waiver, and the company has already paid the fine. No new non-compliances or auditor resignations were reported during the review period.
This is a routine annual compliance filing with no new adverse findings — the only outstanding item is a pending waiver application with NSE for a small prior-year filing lapse. For shareholders, this signals continued regulatory compliance with minor, already-resolved penalties and no material governance red flags.